Table 2 Percentage dose variation of fixed dose method (DoseFIXED) and dose-banding method (DoseBAND) relative to dose based on individual BSA (DoseBSA)
From: Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
DoseFIXED | DoseBAND | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Absolute value of relative difference | Relative difference | Absolute value of relative difference | Relative difference | ||||||||
Usual dose per m 2 (mg) | Mean (s.d.) | ⩾10%a | Mean (s.d.) | Min | Max | Mean (s.d.) | ⩾10%a | Mean (s.d.) | Min | Max | |
Cisplatin | 80 | 8.9 (6.7) | 37 | 1.2 (11.1) | −23 | +44 | 3.9 (2.7) | 2 | −0.3 (4.8) | −14 | +20 |
Docetaxel | 100 | 8.9 (7.0) | 35 | 1.2 (11.3) | −21 | +43 | 4.1 (2.9) | 3 | 0.01 (5.1) | −12 | +20 |
Paclitaxel | 100 | 10.0 (7.6) | 41 | 1.5 (12.5) | −25 | +35 | 3.9 (3.2) | 4 | 1.4 (4.9) | −14 | +17 |
Doxorubicin | 60 | 9.2 (7.3) | 41 | 1.3 (11.7) | −23 | +42 | 4.1 (3.2) | 4 | 0.003 (5.2) | −13 | +22 |
Topotecan | 1.5 | 10.1 (6.8) | 43 | 1.5 (12.2) | −25 | +31 | 4.4 (2.9) | 4 | −0.4 (5.3) | −14 | +14 |
Irinotecan | 350 | 9.3 (7.3) | 40 | 1.3 (11.7) | −21 | +41 | 4.1 (2.9) | 5 | −0.9 (5.0) | −13 | +17 |
